"The present study documents the potential efficacy of topical dorzolamide for treating CME in patients with RP. We observed that some patients may show a “rebound phenomenon” with continued use of the medication; hence, there is a need for careful follow-up in patients being treated."
Monday, May 15, 2006
TOPICAL DORZOLAMIDE IN PATIENTS WITH CME AND RP
ScienceDirect - American Journal of Ophthalmology : Topical Dorzolamide for the Treatment of Cystoid Macular Edema in Patients With Retinitis Pigmentosa This study's purpose was to determine if topical dorzolamide would be effective in treating CME in patients with RP. Of 15 patients with CME and RP, who were treated with w/ topical dorzolamide TID, 87% showed significant decrease in retinal thickness in at least one eye after at least four weeks, 33% showed significant improvement in both eyes, and 31% of those who showed improvment showed worsening with continued treatment. The study concluded:
Subscribe to:
Post Comments (Atom)
Interesting article. Thanks for posting it.
ReplyDelete